← GeneDx overview

GeneDx vs Tempus AI, Inc. Class A Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GeneDx Holdings Corp. (WGS)

Q3 2026
▲2▼2

GeneDx Faces Legal Woes, Reaffirms Outlook, Raises Capital

  • Securities Fraud Lawsuits Continue Multiple law firms filed securities fraud class actions over the Fabric Genomics acquisition, which was written down by $31.2 million and triggered a 49% stock collapse. The August 3 lead plaintiff deadline keeps legal uncertainty alive, weighing on shares.

    This is the main negative force, with ongoing lawsuits and a key deadline during the period.

  • Reaffirmed 2026 Revenue Outlook GeneDx reaffirmed its 2026 revenue outlook, easing fears of further downgrades after a 12% guidance cut. This signals management confidence in the business despite legal challenges.

    This positive news provided reassurance to investors and supported the stock.

  • Raised $5 Million from Blackstone Affiliate GeneDx raised about $5 million from a Blackstone affiliate at $61 per share, signaling confidence from a major investor. This capital infusion strengthens the balance sheet amid ongoing legal costs.

    This capital raise is a new positive development that shows institutional support.

  • Q2 Net Loss Leaves Profitability Unproven Q2 revenue was $114.44 million but net loss was $17.74 million, leaving profitability unproven. This financial performance raises concerns about the company's path to profitability.

    The Q2 earnings report is a key new data point that highlights ongoing financial challenges.

July 2026
▲2▼2

GeneDx Faces Legal Woes, Reaffirms Outlook, Raises Capital

  • Securities Fraud Lawsuits Continue Multiple law firms filed securities fraud class actions over the Fabric Genomics acquisition, which was written down by $31.2 million and triggered a 49% stock collapse. The August 3 lead plaintiff deadline keeps legal uncertainty alive, weighing on shares.

    This is the main negative force, with ongoing lawsuits and a key deadline during the period.

  • Reaffirmed 2026 Revenue Outlook GeneDx reaffirmed its 2026 revenue outlook, easing fears of further downgrades after a 12% guidance cut. This signals management confidence in the business despite legal challenges.

    This positive news provided reassurance to investors and supported the stock.

  • Raised $5 Million from Blackstone Affiliate GeneDx raised about $5 million from a Blackstone affiliate at $61 per share, signaling confidence from a major investor. This capital infusion strengthens the balance sheet amid ongoing legal costs.

    This capital raise is a new positive development that shows institutional support.

  • Q2 Net Loss Leaves Profitability Unproven Q2 revenue was $114.44 million but net loss was $17.74 million, leaving profitability unproven. This financial performance raises concerns about the company's path to profitability.

    The Q2 earnings report is a key new data point that highlights ongoing financial challenges.

Latest
▲2▼1

GeneDx hit by Fabric Genomics lawsuits, then reaffirms outlook and raises cash

  • Securities class actions pile up over Fabric Genomics Multiple law firms filed class actions claiming GeneDx misled investors about the Fabric Genomics acquisition, the durability of reimbursement rates and gross margins. Lawsuits can mean legal costs, management distraction and reputational damage, all of which weigh on the stock.

    The wave of lawsuits is the dominant new negative force this period.

  • GeneDx reaffirms 2026 outlook GeneDx stood by its full-year 2026 revenue guidance, signaling the May guidance cut is holding rather than worsening. For investors worried about another downgrade, a stable outlook removes a key fear and supports the share price.

    Reaffirmed guidance is the main new fundamental signal countering the legal overhang.

  • Blackstone affiliate injects fresh capital GeneDx raised about $5 million selling shares at $61 each to a Blackstone affiliate. The sum is small, but backing from a major investor signals confidence and adds cash as the company expands into pediatric and NICU markets.

    New outside capital and a marquee backer are a fresh positive for the stock.

  • Q2 shows revenue but still a net loss Second-quarter revenue was $114.44 million with a $17.74 million net loss. Sales are real, but the company still loses money, so the path to profit remains unproven and keeps pressure on the shares.

    The Q2 numbers are new and show both the growth story and its profitability risk.

▼1

GeneDx Legal Cloud Persists as August 3 Lead Plaintiff Deadline Nears

  • August 3 lead plaintiff deadline keeps lawsuit in focus Investors have until August 3, 2026 to ask to lead the securities fraud class action over the Fabric Genomics deal. The deadline keeps the allegations in the news and stretches out uncertainty, which tends to hold the stock down until the matter is resolved.

    This is the only new development this period — the deadline is approaching and multiple firms are reminding investors, which keeps the legal overhang active.

▼3

GeneDx Lawsuits Over Fabric Genomics Keep Piling Up

  • Law firms keep pressing the Fabric Genomics fraud case Multiple law firms are now investigating or reminding investors about the securities fraud class action tied to the Fabric Genomics deal. Each new firm joining keeps the legal cloud over GeneDx, and the threat of penalties and damaged management credibility weighs on the stock.

    Shows the legal pressure is broadening, not fading, which is the main new force on WGS.

  • August 3 deadline keeps the lawsuit in the spotlight Investors have until August 3, 2026 to ask to lead the case. That date keeps the allegations in the news and stretches out the uncertainty, which tends to hold the stock down until the matter is resolved.

    The approaching deadline is a concrete new event that keeps negative attention on the stock.

  • The $31.2 million write-off is the heart of the case The lawsuits center on the Fabric Genomics purchase, which GeneDx wrote down by $31.2 million — nearly all the cash it paid a year earlier. That failed deal, plus a 12% guidance cut, is what triggered the 49% stock collapse.

    Explains the underlying business failure that all the new legal stories are built on.

Q2 2026
▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

June 2026
▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

▼3

GeneDx Hit by Securities Fraud Lawsuits Over Fabric Genomics

  • Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.

    This is the main new event of the period and directly explains negative pressure on WGS.

  • Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.

    The deadline is a new concrete development that sustains negative attention on WGS.

  • CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.

    This is a new insider transaction that may affect investor sentiment.

Tempus AI, Inc. Class A Common Stock (TEM)

Q3 2026
▲3▼1

Tempus AI swings to profit, buys Personalis, wins trial and FDA clearances

  • Q2 profit and raised guidance Tempus AI reported Q2 2026 net income of $5.64 million, swinging to a profit, and raised full-year revenue guidance to $1.60–$1.61 billion. This shows the company is growing and becoming more financially stable.

    Profitability and raised guidance are key positive financial developments that directly affect investor confidence and stock price.

  • Personalis acquisition and trial win Tempus agreed to buy Personalis for $1.5 billion to add minimal residual disease testing, and a phase 3 mRNA melanoma trial win sent shares up 39.5%. These expand its cancer testing and boost its technology.

    The acquisition and trial success are major strategic moves that drive growth and market excitement.

  • FDA clearances and partnership expansion Tempus won FDA clearance for two AI-ECG cardiac products and expanded a multi-year partnership with Moderna and Merck. These open new markets and strengthen its AI healthcare offerings.

    Regulatory approvals and partnerships are concrete milestones that validate the company's technology and drive future revenue.

  • Legal probes and insider stock sale Law firms are investigating whether Tempus's existing Personalis stake created conflicts of interest, and its legal chief sold $1.5 million in stock (tax withholding). These keep deal-related uncertainty alive.

    Legal scrutiny and insider selling can undermine investor trust and create overhang on the stock.

August 2026
▲3

Tempus wins FDA clearances, expands Moderna/Merck deal, Personalis buyout nears close

  • FDA clears two more AI heart tools Tempus won FDA clearance for two AI-ECG cardiac products, ECG-MR and ECG-PH, adding to its cleared heart lineup. Each new cleared product opens another billing stream and shows regulators keep accepting its AI, which supports the growth story behind the stock.

    New regulatory wins expand Tempus's commercial product pipeline and revenue potential.

  • Moderna and Merck expand Tempus partnership Tempus signed an expanded multi-year deal with Moderna and Merck to collect tissue and blood and run sequencing for their personalized mRNA cancer therapy. It deepens ties to major drugmakers and adds recurring service revenue, reinforcing demand for Tempus's testing and data.

    New commercial collaboration with major pharma partners directly boosts Tempus's service demand.

  • Personalis takeover looks set to close BTIG downgraded Personalis to Neutral, saying Tempus is highly likely to close its $1.5 billion acquisition at the agreed $16.25 per share, with no higher bidder expected. Removing deal uncertainty lets investors focus on the combined cancer-testing business.

    Reduced uncertainty around a major acquisition is a positive catalyst for Tempus shares.

  • Legal probes and insider sale add noise Law firms investigated whether Tempus's existing stake in Personalis created conflicts in the sale, and its legal chief sold $1.5 million of stock. The sale was just tax withholding, not a warning, but the probes keep deal-related uncertainty alive.

    These are the main counterweights to the positive deal and product news this period.

Latest
▲3

Tempus wins FDA clearances, expands Moderna/Merck deal, Personalis buyout nears close

  • FDA clears two more AI heart tools Tempus won FDA clearance for two AI-ECG cardiac products, ECG-MR and ECG-PH, adding to its cleared heart lineup. Each new cleared product opens another billing stream and shows regulators keep accepting its AI, which supports the growth story behind the stock.

    New regulatory wins expand Tempus's commercial product pipeline and revenue potential.

  • Moderna and Merck expand Tempus partnership Tempus signed an expanded multi-year deal with Moderna and Merck to collect tissue and blood and run sequencing for their personalized mRNA cancer therapy. It deepens ties to major drugmakers and adds recurring service revenue, reinforcing demand for Tempus's testing and data.

    New commercial collaboration with major pharma partners directly boosts Tempus's service demand.

  • Personalis takeover looks set to close BTIG downgraded Personalis to Neutral, saying Tempus is highly likely to close its $1.5 billion acquisition at the agreed $16.25 per share, with no higher bidder expected. Removing deal uncertainty lets investors focus on the combined cancer-testing business.

    Reduced uncertainty around a major acquisition is a positive catalyst for Tempus shares.

  • Legal probes and insider sale add noise Law firms investigated whether Tempus's existing stake in Personalis created conflicts in the sale, and its legal chief sold $1.5 million of stock. The sale was just tax withholding, not a warning, but the probes keep deal-related uncertainty alive.

    These are the main counterweights to the positive deal and product news this period.

July 2026
▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.